Galectin-9 as a prognostic factor with antimetastatic potential in breast cancer

Clinical Cancer Research

Volumn 11, Issue 8, 2005, Pages 2962-2968

  Irie, Akemi ^a   Yamauchi, Akira ^a,b   Kontani, Keiichi ^a   Kihara, Minoru ^a   Liu, Dage ^a   Shirato, Yukako ^b   Seki, Masako ^b   Nishi, Nozomu ^a,b   Nakamura, Takanori ^a   Yokomise, Hiroyasu ^a   Hirashima, Mitsuomi ^a,b  

^a KAGAWA UNIVERSITY   (Japan)

^b GalPharma Co Ltd   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ECALECTIN; GALECTIN; SCLEROPROTEIN; UNCLASSIFIED DRUG;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER CELL; CANCER SURVIVAL; CELL AGGREGATION; CELL CULTURE; CELL PROLIFERATION; CELL STRAIN MCF 7; CONTROLLED STUDY; EXPRESSION VECTOR; FEMALE; FOLLOW UP; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; METASTASIS; METASTASIS INHIBITION; MOUSE; MULTIVARIATE ANALYSIS; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

ADULT; ANIMALS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL ADHESION; CELL AGGREGATION; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE-FREE SURVIVAL; EXTRACELLULAR MATRIX PROTEINS; FEMALE; FOLLOW-UP STUDIES; GALECTINS; HUMANS; IMMUNOHISTOCHEMISTRY; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, NUDE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; PLASMIDS; PROGNOSIS; TRANSFECTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 20244382990     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-0861     Document Type: Article

References (26)

1. Hennessy C, Henry JA, May FE, Westley BR, Angus B, Lennard TW. Expression of the antimetastatic gene nm23 in human breast cancer: an association with good prognosis. J Natl Cancer Inst 1991;83:281-5.
2. Belev B, Aleric I, Vrbanec D, Petrovecki M, Unusic J, Jakic-Razumovic J. Nm23 gene product expression in invasive breast cancer-immunohistochemical analysis and clinicopathological correlation. Acta Oncol 2002;41:355-61.
3. Hartsough MT, Clare SE, Mair M, et al. Elevation of breast carcinoma Nm23-H1 metastasis suppressor gene expression and reduced motility by DNA methylation inhibition. Cancer Res 2001;61:2320-7.
4. Keyomarsi K, Tucker SL, Buchholz TA, et al. Cyclin E and survival in patients with breast cancer. N Engl J Med 2002;347:1566-75.
5. Gitt MA, Barondes SH. Evidence that a human soluble β-galactoside- binding lectin is encoded by a family of genes. Proc Natl Acad Sci U S A 1986;83:7603-7.
6. Paroutaud P, Levi G, Teichberg VI, Strosberg AD. Extensive amino acid sequence homologies between animal lectins. Proc Natl Acad Sci U S A 1987;84:6345-8.
7. Caron M, Bladier D, Joubert R. Soluble galactoside-binding vertebrate lectins: a protein family with common properties. Int J Biochem 1990;22:1379-85.
8. Barondes SH, Castronovo V, Cooper DN, et al. Galectins, a family of animal-galactoside-binding lectins. Cell 1994;76:597-8.
9. Rorive S, Belot N, Decaestecker C, et al. Galectin-1 is highly expressed in human gliomas with relevance for modulation of invasion of tumor astrocytes into the brain parenchyma. Glia 2001;33:241-55.
10. Warfield PR, Makker PN, Raz A, Ochieng J. Adhesion of human breast carcinoma to extracellular matrix proteins is modulated by galectin-3. Invasion Metastasis 1997;17:101-12.
11. Nakamura M, Inufusa H, Adachi T, et al. Involvement of galectin-3 expression in colorectal cancer progression and metastasis. Int J Oncol 1999;15:143-8.
12. Glinsky VV, Huflejt ME, Glinsky GV, Deutscher SL, Quinn TP. Effects of Thomsen-Friedenreich antigen-specific peptide P-30 on β-galactoside- mediated homotypic aggregation and adhesion to the endothelium of MDA-MB-435 human breast carcinoma cells. Cancer Res 2000;60:2584-8.
13. Nangia-Makker P, Hogan V, Honjo Y, et al. Inhibition of human cancer cell growth and metastasis in nude mice by oral intake of modified citrus pectin. J Natl Cancer Inst 2002;94:1854-62.
14. Bartolazzi A, Gasbarri A, Papotti M, et al. Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions. Lancet 2001;357:1644-50.
15. Kageshita T, Kashio Y, Yamauchi A, et al. Possible role of galectin-9 in cell aggregation and apoptosis of human melanoma cell lines and its clinical significance. Int J Cancer 2002;99:809-16.
16. Matsushita N, Nishi N, Seki M, et al. Requirement of divalent galactoside-binding activity of ecalectin/galectin-9 for eosinophil chemoattraction. J Biol Chem 2000;275:8355-60.
17. Matsumoto R, Matsumoto H, Seki M, et al. Human ecalectin, a variant of human galectin-9, is a novel eosinophil chemoattractant produced by T lymphocytes. J Biol Chem 1998;273:16976-84.
18. Kallioniemi OP, Holli K, Visakorpi T, Koivula T, Helin HH, Isola JJ. Association of c-erbB-2 protein over-expression with high rate of cell proliferation, increased risk of visceral metastasis and poor long-term survival in breast cancer. Int J Cancer 1991;49:650-65.
19. Giai M, Roagna R, Ponzone R, De Bortoli M, Dati C, Sismondi P. Prognostic and predictive relevance of c-erbB-2 and ras expression in node positive and negative breast cancer. Anticancer Res 1994;14:1441-50.
20. Bozcuk H, Uslu G, Pestereli E, et al. Predictors of distant metastasis at presentation in breast cancer: a study also evaluating associations among common biological indicators. Breast Cancer Res Treat 2001;68:239-48.
21. Thor AD, Moore DH II, Edgerton SM, et al. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J Natl Cancer Inst 1992;84:845-55.
22. MacGrogan G, Bonichon F, de Mascarel I, et al. Prognostic value of p53 in breast invasive ductal carcinoma: an immunohistochemical study on 942 cases. Breast Cancer Res Treat 1995;36:71 -81.
23. van't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530-6.
24. van de Vijver MJ, He YD, van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002;347:1999-2009.
25. Wada J, Ota K, Kumar A, Wallner El, Kanwar YS. Developmental regulation, expression, and apoptotic potential of galectin-9, a p-galactoside binding lectin. J Clin Invest 1997;99:245-61.
26. Tsuchiyama Y, Wada J, Zhang H, et al. Efficacy of galectins in the amelioration of nephrotoxic serum nephritis in Wistar Kyoto rats. Kidney Int 2000;58:1941-52.